Genome & Company (KOSDAQ:314130)
4,015.00
-205.00 (-4.86%)
At close: Oct 22, 2026
Genome & Company Financials Overview
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 24,461 | 24,587 | 27,745 | 14,296 | 14,085 | 451.25 |
Revenue Growth | 1.84% | -11.38% | 94.07% | 1.50% | 3021.27% | 199.67% |
Gross Profit Gross Profit Growth | 13,331 | 13,406 | 15,670 | 4,064 | 5,598 | 374.24 |
Operating Income Operating Income Growth | -29,189 | -29,234 | -24,199 | -55,092 | -57,512 | -36,087 |
Net Income Net Income Growth | -41,361 | -6,428 | -20,112 | -47,466 | -51,838 | -34,117 |
Earnings Per Share EPS Growth | -1180.23 | -205.30 | -660.20 | -1680.81 | -1841.50 | -1269.10 |
EPS Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
South Korea South Korea Growth | 13,716 | 13,369 | 6,301 | 2,386 | 14,085 | 451.25 |
Asia Asia Growth | 7,213 | 5,951 | 4,428 | 7,188 | - | - |
Europe Europe Growth | 401.62 | 785.01 | 7,372 | 269.13 | - | - |
South America South America Growth | 47.08 | 31.13 | 29.46 | 15.04 | - | - |
North America North America Growth | 3,073 | 4,437 | 9,604 | 4,386 | - | - |
Oceania Oceania Growth | 9.42 | 13.71 | 10.97 | 52.16 | - | - |
Total Total Growth | 24,461 | 24,587 | 27,745 | 14,296 | 14,085 | 451.25 |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 64,301 | 36,830 | 80,930 | 86,272 | 106,699 | 77,164 |
Total Debt Total Debt Growth | 24,811 | 18,967 | 32,024 | 26,453 | 6,291 | 6,826 |
Net Cash (Debt) Net Cash Growth | 39,490 | 17,862 | 48,906 | 59,819 | 100,408 | 70,338 |
Net Cash Growth | 23.96% | -63.48% | -18.24% | -40.42% | 42.75% | -34.77% |
Net Cash Per Share Net Cash Per Share Growth | 1126.83 | 570.49 | 1605.36 | 2118.26 | 3566.88 | 2616.46 |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -17,550 | -18,387 | -16,331 | -32,224 | -43,550 | -26,159 |
Capital Expenditures CapEx Growth | -540.08 | -284.66 | -3,970 | -18,853 | -6,849 | -2,875 |
Free Cash Flow Free Cash Flow Growth | -18,090 | -18,671 | -20,301 | -51,077 | -50,399 | -29,034 |
Free Cash Flow Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 54.50% | 54.53% | 56.48% | 28.43% | 39.74% | 82.94% |
Operating Margin | -119.33% | -118.90% | -87.22% | -385.37% | -408.34% | -7997.20% |
Pretax Margin | -182.27% | -35.25% | -101.69% | -362.72% | -412.03% | -7978.71% |
Profit Margin | -169.09% | -26.14% | -72.49% | -332.02% | -368.05% | -7560.62% |
FCF Margin | -73.95% | -75.94% | -73.17% | -357.28% | -357.83% | -6434.20% |
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 22, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 8.58 | 9.70 | 3.07 | 12.33 | 17.46 | 1038.96 |